16202688Odenike O, Tefferi ASeminars in oncologyPrimary MyelofibrosisAndrogens; Angiogenesis Inhibitors; Antineoplastic Agents; Azacitidine; Benzamides; Chronic Disease; Decitabine; Erythropoietin; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Quinolones; Recombinant ProteinsConventional and new treatment options for myelofibrosis with myeloid metaplasia. Semin Oncol. 2005 Aug; 32(4):422-31.Semin Oncol2005-08-01T00:00:002005Conventional and new treatment options for myelofibrosis with myeloid metaplasia.prns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD000970Chemicals & Drugs40723510.435494Antineoplastic AgentsD000728Chemicals & DrugsPhysiology541640.930447AndrogensD001549Chemicals & Drugs942260.914079BenzamidesD001374Chemicals & Drugs551370.925001AzacitidineD002908DisordersLiving Beings3839680.756988Chronic DiseaseD004921Chemicals & Drugs59910.955329ErythropoietinAuthorship 280501D010879Chemicals & Drugs1102720.858236PiperazinesD006801Living Beings2262862810.130064HumansD015363Chemicals & Drugs42600.951951QuinolonesMedicine-Hematology and OncologyD020533Chemicals & DrugsPhysiology1073090.812525Angiogenesis Inhibitors0.2743620.2743621authors10.2514has subject areaD011743Chemicals & Drugs1373700.795286PyrimidinesD011994Chemicals & Drugs36610140.836817Recombinant ProteinsD055728Disorders19550.957039Primary MyelofibrosisD000068877451260.961428Imatinib MesylateUniversity of ChicagoOlatoyosiOdenikew21tDq8cEun5hHlsaUXv9Gq0+s+oOlatoyosi Odenike41.78927490000000-87.60125000000000399Odenike, OlatoyosiProfessortrue1ProfessorProfessor